A method of reversing, ameliroating or slowing progression of at least one symptom of Parkinson's disease in a patient in need thereof, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to reverse, ameliorate or slow progression of said at least one symptom of Parkinson's disease, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 wherein Ri is one of an N-acyl group, a substituted or unsubstituted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
The answer lies in what you are comparing it to
Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia
These unstable molecules are produced during normal metabolism and also increase due to pollution, stress, illness, and certain medications
